about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskGermline mutations in RAD51D confer susceptibility to ovarian cancerMosaic PPM1D mutations are associated with predisposition to breast and ovarian cancerIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Open access follow-up for lung cancer: patient and staff satisfaction.Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersGene-gene interactions in breast cancer susceptibility.Thalidomide in the treatment of cancer.Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.Prediction of the response of colorectal cancer to systemic therapy.Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status.Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Cancer knowledge of the general public in the United Kingdom: survey in a primary care setting and review of the literature.Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriersAn original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersCommon variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation CarriersA nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.Radiotherapy for ductal carcinoma in situ.Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskCommon alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.Robust diagnostic genetic testing using solution capture enrichment and a novel variant-filtering interface.Characterization and Genomic Localization of a SMAD4 Processed Pseudogene.Left and right sided large bowel cancerHistopathology of melanocytic lesions in a family with an inherited BAP1 mutation.Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.Morbidity of tamoxifen-perceptions of patients and healthcare professionals.
P50
Q21144874-25720F14-A627-42B5-899D-21CE88B0EEF1Q27008356-AA4A4EE3-FCE0-4D29-B6D3-DAA9CFFB4837Q28245028-DADAF67C-7581-40CE-A201-6A666D00D5F7Q28388006-7F0C540F-F5A2-451E-91E5-59CB56D63968Q30252854-8FC15A9D-9386-482D-B4EC-6DDDE421C5B8Q30482279-12376396-B4EC-4900-8A0D-88B28D34E03BQ31043651-1CB5F600-68C5-48F9-B9BF-632E11B26285Q33614244-200FDC8D-A461-48E9-87BA-700B7A406E00Q34017597-D7CD4583-588E-408A-906F-B9FDEDF09A17Q34121220-B62B7A62-CBF6-4159-BDEA-8FC6FE31036BQ34213403-F6C97889-CF24-4A0A-AA70-907BA374A0C8Q34569963-45D2A380-B7A5-4381-AC03-19894CBE1581Q34700093-B9A5BB5E-A85D-4CCF-8AA6-B1E158E76C0FQ34806825-91E02E34-B49E-4649-9B2B-A1F73C359EFDQ34963894-22C09EB6-72E9-485F-A75C-65BE10394730Q35155449-8D05AECE-B2DD-4CB9-A396-D3E5B2860DE7Q35170798-E34ECC90-44B7-4424-9C50-7ABDCF390CF8Q35523236-F2FA3402-3D0B-4278-BCF3-3C40795CD772Q35618307-8014C674-37A7-4C1F-AD33-4D3AFB54622DQ35870067-94222D0E-9E93-47D7-97B2-B26C9C18E3B4Q35889575-198DD12E-3C2A-4670-A9F8-043EBDD37780Q35957703-503F7161-D7CB-4FFF-9203-DA92B5FD4732Q36072765-22602528-6E90-474C-A8F0-AAA991F01E72Q36087170-225AF32B-636E-4152-9039-1D76DCA484E8Q36152991-51F17CC9-19BC-4561-8AB3-ED9BEB48ECA2Q36178189-4D6C4EB6-71DA-498C-8AA4-6E70C69A0969Q36245609-E9CAD239-7E66-4560-8DFB-AACB2121E740Q36280191-0936DEE6-F4CE-43FB-9EB9-2561D06347C8Q36356727-45C43F5A-14C6-4117-BF2E-E4C321B6928EQ36393232-5CF712AC-87AA-406C-8B36-21E4B28D0CBFQ36444722-9CF1BDB4-CFE0-4E78-81B5-8AD17D11AC9CQ36720814-D5635C4B-AE66-4C61-B722-B577FB17A8CEQ36839777-21789005-1D7C-4F96-A22A-E79BCE162665Q38717239-9B57CA2A-5A37-4223-9B99-B20FAE373B75Q42177337-1AB06B1F-020B-4AD5-B491-749E85FB68A0Q42687564-877F65D7-396A-4502-A41F-20FADFE6617BQ42777241-3435CC23-121C-4A36-99CA-C606D115D972Q42919440-A9FE1EDE-20F3-46F4-81FA-80197FB2CD06Q43254499-0F724055-6FEC-408F-96B2-BB50CC35AE03Q44765493-78CE8380-B6E8-46E6-86B9-3D05ECD44203
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-ca
researcher
@en-gb
ymchwilydd
@cy
հետազոտող
@hy
name
Julian Weldon Adlard
@ast
Julian Weldon Adlard
@cy
Julian Weldon Adlard
@de
Julian Weldon Adlard
@en
Julian Weldon Adlard
@en-ca
Julian Weldon Adlard
@en-gb
Julian Weldon Adlard
@es
Julian Weldon Adlard
@fr
Julian Weldon Adlard
@it
Julian Weldon Adlard
@nl
type
label
Julian Weldon Adlard
@ast
Julian Weldon Adlard
@cy
Julian Weldon Adlard
@de
Julian Weldon Adlard
@en
Julian Weldon Adlard
@en-ca
Julian Weldon Adlard
@en-gb
Julian Weldon Adlard
@es
Julian Weldon Adlard
@fr
Julian Weldon Adlard
@it
Julian Weldon Adlard
@nl
prefLabel
Julian Weldon Adlard
@ast
Julian Weldon Adlard
@cy
Julian Weldon Adlard
@de
Julian Weldon Adlard
@en
Julian Weldon Adlard
@en-ca
Julian Weldon Adlard
@en-gb
Julian Weldon Adlard
@es
Julian Weldon Adlard
@fr
Julian Weldon Adlard
@it
Julian Weldon Adlard
@nl
P106
P1153
55175032800
P21
P213
0000 0001 3398 5000
P31
P496
0000-0002-1693-0435